FLT3 and acute myeloid leukemia: Other new targeted agents have been shown to have survival benefits in selected AML subsets when added to standard chemotherapy regimens, including inhibitors of mutant FLT3 (midostaurin, sorafinib, gilteritinib, quizartinib, and others), IDH1 (ivosidenib), and IDH2 (enasidenib).